Dr. Clifford A. Hudis on Why Resistance to HER-2 Therapies Needs to be Further Researched
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professional currently have of HER-2 breast cancer and its resistance to certain therapies.
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professionals currently have of HER-2 breast cancer and its resistance to certain therapies.
Hudis explains that while some studies have suggested that patients would be better off switching therapies due to breast cancer not responding to the treatment, further studies have shown that the benefits of staying with those therapies may outweigh the negative effects. Hudis says that this is a challenge to the idea of drug resistance itself.
T-DXd Maintains QOL, Delays Pain Deterioration in HR+/HER2-Low/Ultralow MBC
September 15th 2024Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.
Read More
